Sai Life Sciences IPO GMP: Sai Life Sciences subscription started on Wednesday, 11 December 2024, and will close on 13 December 2024, as per the schedule. Sai Life Sciences Ltd is gearing up to launch its Rs 3,042.62 crore IPO. This Sai Life Sciences IPO GMP subscription is an amalgamation of a fresh issue of Rs 950 crore (1.73 crore shares) and an offer-for-sale of Rs 2,092.62 crore (3.81 crore shares). The company is gearing up to list on both the BSE and NSE.
Table of Contents
Sai Life Sciences IPO GMP Price band
- Retail investors must make a minimum investment of Rs 14,823 to participate.
- Small NII investors need to invest at least Rs 207,522 for 378 shares, equivalent to 14 lots.
- Large NII investors need a minimum investment of Rs 1,007,964 for 1,836 shares, which is 68 lots.
- The price band is set at ₹522 to ₹549 per share with a face value of ₹1.
- Kfin Technologies Ltd has been appointed as the official registrar for this offering. Kotak Mahindra Capital Company Ltd, Jefferies India Pvt Ltd, Morgan Stanley India Company Pvt Ltd, and IIFL Securities Ltd are the book-running lead managers in this IPO.
Sai Life Sciences Subscribed over 0.85x on its first day of subscription wherein QIB subscribed 2.52x, NII subscribed 0.16x, and RII subscribed 0.19x. Subscribed over 0.85x on its first day till 5.00 PM on 11th December.
Sai Life Sciences IPO GMP Latest
The most recent Sai Life Sciences IPO GMP is Rs 42, as of 11th December 2024 at 11:01 AM. The IPO has a price band of Rs 549. The estimated listing price for Sai Life Sciences Ltd is Rs 591, reflecting a potential gain of 7.65% per share.
For the IPO, the Retail Subject to Sauda is Rs 900, and the Small HNI Subject to Sauda is Rs 12,600. The GMP ranges from a low of Rs 22 to a high of Rs 42.
About the Company
- Sai Life Sciences Ltd, founded in January 1999, specializes in researching, developing, and manufacturing small-molecule new chemical entities.
- The company provides customized services to biotech firms and global pharmaceutical companies.
- In FY 2024, Sai Life Sciences provided services to over 280 pharmaceutical companies, including more than 230 in September 2024.
- The company worked with 18 of the top 25 pharmaceutical companies by revenue in 2023.
- Services were offered across countries such as the US, UK, Europe, and Japan.
The business development team has 16 professionals, with six in the US, nine in the UK and Europe, and one in Japan. - The company offers capabilities in CMC/CDMO and CRO services, including integrated discovery across biology, chemistry, and drug metabolism.
- As of 30th September 2024, the company had 2,353 scientific staff, including 302 Ph.D and 1,475 master’s degrees.
- The total employee count was 3,135, covering the CRDMO value chain.
Revenue: The company generated Rs 693.35 crore in revenue during the period ended on 30th September 2024.
Profit After Tax (PAT): The company earned a profit of Rs 28.01 crore after deducting taxes.
Net Worth: The company’s net worth, which represents the total value of the company’s assets minus its liabilities, is Rs 1,044.75 crore.
Financial Position Assets: The company’s total assets amounted to Rs 2,476.78 crore.
Reserves and Surplus: The company has accumulated reserves and a surplus of Rs 1,025.44 crore.
Aim of the Sai Life Sciences IPO GMP
- The company plans to use the Net Proceeds for the following purposes:
- Repayment or prepayment of all or part of its outstanding borrowings.
- General corporate purposes.
GMP Update !
— Dr. Mukul Agrawal (@themukulagrawal) December 10, 2024
Mainboard IPOs –
International Gemmological Institute IPO – GMP: ₹146
Inventurus Knowledge Solutions IPO – GMP: ₹350
Mobikwik IPO – GMP: ₹130
Sai Life Sciences IPO – GMP: ₹28
Vishal Mega Mart IPO – GMP: ₹25
SME IPOs –
Rosmerta Digital Services – GMP: ₹22… pic.twitter.com/g2u6GqMJ4Y
Jay Chavda He is the Founder and Writer of businesspulsecare.com. He is an I.T Engineer, Freelancer, Businessman. He posts Business, Stock/Share Market, Finance Related News and updates on the website. 🔗